Unlike other companies grappling with evolving trade policy, Pfizer did not revise its full-year outlook on Tuesday.

The incoming CEO is David Hallal, the chairman of the company's board. As CEO, he succeeds Jay Backstrom, who is transitioning into a role as strategic advisor. Hallal served in several managerial ...